医学
疾病
西医
重症监护医学
转化医学
中医药
转化研究
替代医学
生物药物
临床实习
中西医结合
药物开发
精密医学
梅德林
纤维化
药品
中国
关键路径
试验药物
生物信息学
基础研究
炎症
作者
Qili Xiao,Delong Mo,Gang Liu,Yuting Xu,Yan Chen,Chuanjian Lu
摘要
Despite the current absence of clinically approved antifibrotic drugs, this review synthesizes critical advances in mechanistic understanding and emerging therapeutic strategies. We highlight the urgent unmet clinical need and propose integrative medicine as a promising paradigm shift for fibrosis management. While no therapies yet fully reverse established fibrosis, this review provides three key contributions: Systematically maps molecular pathways from inflammation to fibrosis, identifies knowledge gaps in TCM translational research, and proposes a "control-prevent-reverse" framework for future drug development. These insights are timely given the rising CD prevalence in China and increasing NIH funding for antifibrotic research.
科研通智能强力驱动
Strongly Powered by AbleSci AI